Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
PHP Toggle Menu

Category: Pexa-Vec

Transgene Provides an Update after the Interim Futility Analysis of the PHOCUS Study of Pexa-Vec in Liver Cancer

20190807 – Transgene Update EN

Published 7 August 2019
Categorized as 2019, Pexa-Vec, Press release

Transgene Provides Update on PHOCUS Study of Pexa-Vec in Liver Cancer Following Planned Interim Futility Analysis

20190802 PHOCUS Interim Analysis US

Published 2 August 2019
Categorized as 2019, Pexa-Vec, Press release

Transgene’s Lead Oncolytic Virus Pexa-Vec Triggers Strong Anti-Tumor Immunity after Intravenous Administration

20180604 PR ASCO Pexa-vec neoadjuvant data EN

Published 4 June 2018
Categorized as 2018, Pexa-Vec, Press release

Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity

Alan Anthoney, et al. ASCO 2018, June 2018 – Abstract available on the ASCO website Download the poster here Poster Presentation

Published 17 May 2018
Categorized as -others, 2018, Pexa-Vec, Publication

Transgene to Present New Clinical Data on Oncolytic Virus Pexa-Vec at ASCO 2018

20180517 PR ASCO poster accepted EN

Published 17 May 2018
Categorized as 2018, Pexa-Vec, Press release

Transgene and Institut Bergonié Present a Poster on the METROmaJX Trial (Oncolytic Virus Pexa-Vec + Metronomic Cyclophosphamide) at ESMO 2017 Congress

20170907-ESMO-Metromajx-poster-EN

Published 7 September 2017
Categorized as 2017, Pexa-Vec, Press release

A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors

Maud Toulmonde, et al. ESMO 2017, September 11, 2017, 13:15 – 14:15, Hall 8 Download the poster here Poster Presentation

Published 7 September 2017
Categorized as -others, 2017, Pexa-Vec, Publication Tagged Oncolytic virus, Poster presentation

First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer

PR Pexa-Vec nivo EN

Published 31 July 2017
Categorized as 2017, Pexa-Vec, Press release

SillaJen and Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer

20170424 PR PHOCUS FPI EU – EN

Published 24 April 2017
Categorized as 2017, Pexa-Vec, Press release

Transgene and Institut Bergonié Start the Phase 2 Part of the METROmaJX Trial

20170412 PR Metro-JX Ph2 EN

Published 12 April 2017
Categorized as 2017, Pexa-Vec, Press release

Posts pagination

Page 1 Page 2 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
Menu